The advent of commercially available type-specific serologies, in combination with counseling and antiviral therapy has provided the tools to initiate more active preventative strategies for the reduction of HSV-2 transmission. An effective HSV vaccine could enhance these tools even more. However, to effectively implement a preventative strategy better understanding is needed of the biological and behavioral correlates of HSV-2 transmission.
The specific aims of this proposal are: 1) To determine, based on the duration of sex partnerships prior to transmission, behavioral, virologic, and immunologic risk factors (such as source partner's lack of awareness of infection, condom use, high viral shedding rates and serostatus) which confer increased risk of HSV transmission, 2) to examine the behavioral, virologic and immunologic aspects of persistently HSV-2 discordant partnerships (non-transmitters). The hypothesis are that most HSV-2 infections are acquired within a short time of initiation of the sex partnership, from persons unaware that they have the infection, and lack of condom use and high viral shedding rates in the source partners are also associated with high risk of HSV transmission to sex partners. The study will be documented by restriction enzyme analysis. Behavioral information will be elicited by interview with both partners and biologic correlates will be assessed using viral isolation, HSV DNA PCR and type-specific serologies. Shedding rate in source partners will be evaluated prospectively using daily viral cultures. Behavioral, virologic and immunologic aspects of protection from transmission will also be assessed in 250 HSV-2 discordant couples. The analysis will use the Cox proportional hazards model to assess the relative risk of characteristics associated with HSV-2 transmission. In exploratory analyses, local and systemic immune responses of HSV-2 exposed but infected persons, and HSV-2 transmitters versus non-transmitters will be assessed. Findings from this study will characterize persons at high risk for transmitting and at high risk for acquiring genital herpes: prevention efforts should focus on these groups.

Project Start
1999-04-01
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Schiffer, Joshua T; Swan, Dave A; Roychoudhury, Pavitra et al. (2018) A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection. J Immunol 201:1522-1535
Traidl, Stephan; Kienlin, Petra; Begemann, Gabriele et al. (2018) Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus-specific type 2 immune responses. J Allergy Clin Immunol 141:1144-1147.e5
Ramchandani, Meena; Selke, Stacy; Magaret, Amalia et al. (2018) Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. Sex Transm Infect 94:568-570
Boucoiran, Isabelle; Mayer, Bryan T; Krantz, Elizabeth M et al. (2018) Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants. Pediatr Infect Dis J 37:627-631
Kleinstein, Sarah E; Shea, Patrick R; Allen, Andrew S et al. (2018) Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2). Genes Immun :
Matrajt, Laura; Gantt, Soren; Mayer, Bryan T et al. (2017) Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. Sci Rep 7:13105
Hensel, Michael T; Peng, Tao; Cheng, Anqi et al. (2017) Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells. J Virol 91:
Gilbert, Peter B; Excler, Jean-Louis; Tomaras, Georgia D et al. (2017) Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. PLoS One 12:e0176428
Celum, Connie; Hong, Ting; Cent, Anne et al. (2017) Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis 215:907-910
Abana, Chike O; Pilkinton, Mark A; Gaudieri, Silvana et al. (2017) Cytomegalovirus (CMV) Epitope-Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects. J Immunol 199:3187-3201

Showing the most recent 10 out of 345 publications